Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo Chinese For Medical Students & Physicians A complete 20-lesson, 300-page Chinese course with a companion app in 21 languages — free forever. Download the free PDF: Amedeo Chinese PDF

Anemia

Free Subscription Articles published in Ann Hematol Retrieve available abstracts of 267 articles: HTML format

Single Articles

July 2026
1. ALRIYAMI M, AlSayegh A, ALRawahi M, Balasuburamanian J, et al
   Between scarcity and surfeit: a familial tale of contradictory iron disorders (beta -thalassemia and iron-refractory iron deficiency anemia).
   Ann Hematol. 2026 Jul 21. doi: 10.1007/s00277-026-07185.
   PubMed     Abstract available
   
   
   
2. COSTA FF, Fertrin KY
   UGT1A1 polymorphisms and gallbladder-related outcomes in sickle cell disease in Brazil.
   Ann Hematol. 2026;105:332.
   PubMed     Abstract available
   
   
   
3. GALVAO F, Maia FS, Rios MR, da Silva Maues JH, et al
   Lactate dehydrogenase (LDH) as a predictor of left atrial remodeling in patients with sickle cell anemia.
   Ann Hematol. 2026 Jul 6. doi: 10.1007/s00277-026-07116.
   PubMed     Abstract available
   
   
   June 2026
4. DU Y, Zhang J, Jin S
   A case report of CD4(-) CD8(+) CD56(-) TCRgammadelta(+) T-large granular lymphocytic leukaemia with severe aplastic anemia and a PNH clone.
   Ann Hematol. 2026 Jun 29. doi: 10.1007/s00277-026-07141.
   PubMed     Abstract available
   
   
   
5. CHANG L, Zhao B, Ruan M, Li W, et al
   Safety, pharmacokinetics, and preliminary efficacy of hetrombopag in pediatric patients with aplastic anemia: A pilot study.
   Ann Hematol. 2026 Jun 18. doi: 10.1007/s00277-026-07088.
   PubMed     Abstract available
   
   
   
6. SLOWLEY A, d'Estrube T, Neukirch K, Kienzle S, et al
   Myelofibrosis and anemia: a German claims data analysis to describe treatment sequencing, survival outcomes, and healthcare resource utilization.
   Ann Hematol. 2026 Jun 4. doi: 10.1007/s00277-026-07033.
   PubMed     Abstract available
   
   
   May 2026
7. ITAGAKI M, Kuwazawa H, Sasaki S, Matsuura M, et al
   Long-term safety and effectiveness of romiplostim in patients with refractory aplastic anemia: a nationwide, all-case, post-marketing surveillance study in Japan.
   Ann Hematol. 2026 May 30. doi: 10.1007/s00277-026-07062.
   PubMed     Abstract available
   
   
   
8. CHEN D, Mo W, Gao L, Liu W, et al
   Sarcopenia-associated CD8(+) T-cell reconstitution predicts poor outcomes in severe aplastic anemia after hematopoietic stem cell transplantation.
   Ann Hematol. 2026 May 29. doi: 10.1007/s00277-026-07093.
   PubMed     Abstract available
   
   
   
9. LI B, Huang L, Yan X, Wang X, et al
   Prevalence of HCV and HIV infections and evaluation of ALT Levels in Patients with transfusion-dependent thalassemia: a cross-sectional study from Nanning, China.
   Ann Hematol. 2026;105:340.
   PubMed     Abstract available
   
   
   
10. AVCU G, Karadas N, Gadashova A, Onder C, et al
    Febrile neutropenia in pediatric acquired aplastic anemia: a 20-year analysis of infections and mortality.
    Ann Hematol. 2026 May 25. doi: 10.1007/s00277-026-06874.
    PubMed     Abstract available
    
    
    
11. MANZ K, Kobrosly M, Crodel CC, Al-Ali H, et al
    Value of functional iron parameters in diagnostic re-assessment of MPN: refinement of iron-deficiency markers by zinc protoporphyrin (ZPP).
    Ann Hematol. 2026;105:294.
    PubMed     Abstract available
    
    
    
12. WANG T, Chen Q, Ma Y, Wang B, et al
    Eltrombopag restores T-cell homeostasis in aplastic anemia by regulating oxidative metabolism and reactive oxygen species levels.
    Ann Hematol. 2026 May 18. doi: 10.1007/s00277-026-07060.
    PubMed     Abstract available
    
    
    
13. SHU H, Yang L, Gao Y, Yun X, et al
    Expanding the genetic spectrum of hereditary spherocytosis: novel mutations and phenotypic heterogeneity from a 55-patient cohort.
    Ann Hematol. 2026;105:321.
    PubMed     Abstract available
    
    
    
14. SAKALIAN O, Huguenin Y, Pissard S, Augis V, et al
    Expanding the PKLR mutation spectrum: discovery of two novel variants in two pediatric cases of pyruvate kinase deficiency.
    Ann Hematol. 2026;105:316.
    PubMed     Abstract available
    
    
    
15. MOHAMMED SALEH MF, Nasiri A, Kotb A, Alfadil H, et al
    Romiplostim in the management of severe aplastic anemia: a comprehensive clinical review.
    Ann Hematol. 2026 May 9. doi: 10.1007/s00277-026-07057.
    PubMed     Abstract available
    
    
    
16. PERRONE S, Tomasello R, Raso S, Annibali O, et al
    Incidence of infections in patients treated with rituximab for autoimmune disorders of hematological Interest or non-Hodgkin lymphoma.
    Ann Hematol. 2026;105:303.
    PubMed     Abstract available
    
    
    
17. NASR NM, Ghaffar NKAE, El Asmar SM, Saber YM, et al
    The role of interleukin-1 beta as an early biomarker for renal dysfunction in Egyptian sickle cell disease patients.
    Ann Hematol. 2026;105:287.
    PubMed     Abstract available
    
    
    
18. BI JY, Zhang YY, Fu HX, He Y, et al
    Haploidentical allogeneic haematopoietic stem cell transplantation for paroxysmal nocturnal haemoglobinuria: a retrospective analysis.
    Ann Hematol. 2026;105:285.
    PubMed     Abstract available
    
    
    
19. SUH K, Newman TV, Yang J, Haubner A, et al
    Real-world use of pharmacologic therapy and chronic blood transfusion in sickle cell disease, 2014-2021.
    Ann Hematol. 2026;105:282.
    PubMed     Abstract available
    
    
    April 2026
20. CHEN L, Zhou Q, Wu S
    Clinical phenotypic heterogeneity in pediatric-thalassemia carriers co-inherited with-globin gene triplication.
    Ann Hematol. 2026;105:278.
    PubMed     Abstract available
    
    
    
21. MARCHESANI S, Antonucci L, Scaramuzzino F, Schettini L, et al
    Renal complications in pediatric sickle cell disease: results from a single-center study.
    Ann Hematol. 2026;105:266.
    PubMed     Abstract available
    
    
    
22. MIRZAEE F, Khamoushi A, Dolati R, Abbasi A, et al
    The role of hydroxyurea in modulating miRNA expression in sickle cell disease: molecular mechanisms and therapeutic implications.
    Ann Hematol. 2026;105:261.
    PubMed     Abstract available
    
    
    
23. GOLDBERG I, Pazgal I, Stark P, Steimatzky A, et al
    Reduced number of endothelial progenitor cells in adult patients with beta thalassemia major.
    Ann Hematol. 2026;105:245.
    PubMed     Abstract available
    
    
    
24. SOLGUN HA, Ozay M
    Effects of vitamin D deficiency and supplementation on myocardial and hepatic iron status and function in children with beta-thalassemia.
    Ann Hematol. 2026;105:246.
    PubMed     Abstract available
    
    
    
25. VARON B, Grau A, Marco NS, Khatib A, et al
    Distinct cellular signatures in aplastic and intermittent phenotypes of immune effector cell-associated hematotoxicity.
    Ann Hematol. 2026;105:243.
    PubMed     Abstract available
    
    
    
26. CHEN ZX, Yang LY, Wang LT, Chen BY, et al
    A case report of congenital sideroblastic anemia caused by a novel ALAS2 mutation in conjunction with thalassemia.
    Ann Hematol. 2026;105:237.
    PubMed     Abstract available
    
    
    
27. ZHANG L, Zhuang J, Huang N, Fu W, et al
    First clinical and molecular characterization of two rare complex beta-globin variants in Chinese population using third generation sequencing.
    Ann Hematol. 2026;105:229.
    PubMed     Abstract available
    
    
    
28. QIN Y, Lu L, Huang X, Li W, et al
    De novo mutations in ANK1 and SPTB cause hereditary spherocytosis: three case reports and literature review.
    Ann Hematol. 2026;105:219.
    PubMed     Abstract available
    
    
    
29. LANG M, Peng L, Jiang N, Li M, et al
    Anti-CD19 chimeric antigen receptor T cells in Evans syndrome of systemic lupus erythematosus.
    Ann Hematol. 2026;105:220.
    PubMed     Abstract available
    
    
    
30. RIBERSANI M, Rubeo A, Colletti R, Regoli D, et al
    Infantile pyknocytosis: A rare but not so rare condition. A new case report.
    Ann Hematol. 2026;105:222.
    PubMed     Abstract available
    
    
    March 2026
31. ZHANG M, Zhang R, Tian Y, Wang H, et al
    Association of CBC-derived inflammatory biomarkers with overall anemia in U.S. youth: NHANES study.
    Ann Hematol. 2026;105:217.
    PubMed     Abstract available
    
    
    
32. YANG L, Chen Y, Wu Y
    Integrated transcriptome-proteome analysis in patients with myelofibrosis-related anemia.
    Ann Hematol. 2026;105:211.
    PubMed     Abstract available
    
    
    
33. ZHENG H, Yu H, Yang X, Deng X, et al
    Aberrant functional connectivity and Granger causality analysis in patients with beta-thalassemia major.
    Ann Hematol. 2026;105:210.
    PubMed     Abstract available
    
    
    
34. ZHAO Y, Gao J, Li Y, Li S, et al
    Clinical value of miR-329-3p in thalassemia and its regulation of TNRC6B expression.
    Ann Hematol. 2026;105:207.
    PubMed     Abstract available
    
    
    
35. SWAMINATHAN A, Kumar NM, Nathany S, Panda NR, et al
    Outcomes of hematopoietic stem cell transplantation in adult sickle cell disease patients: A Single-Center experience from India.
    Ann Hematol. 2026;105:202.
    PubMed     Abstract available
    
    
    
36. ULASI AE, Nri-Ezedi CA, Okpara HC, Ikefuna A, et al
    Adiponectin levels during steady state and vaso-occlusive crisis in Nigerian children with sickle cell anaemia.
    Ann Hematol. 2026;105:196.
    PubMed     Abstract available
    
    
    
37. ENGOLE YM, Makanzu B, Mvunzi TS, Makulo JR, et al
    Elevated tricuspid regurgitation velocity in adults with sickle cell disease and HbAA controls in Kinshasa, Democratic Republic of the Congo: a comparative cross-sectional study.
    Ann Hematol. 2026;105:192.
    PubMed     Abstract available
    
    
    
38. TAN Z, Zhao Y, Hu H, Yu Q, et al
    Comparison of clinical outcomes between early and delayed allogeneic hematopoietic stem cell transplantation for severe aplastic anemia: a single-center retrospective study.
    Ann Hematol. 2026;105:186.
    PubMed     Abstract available
    
    
    
39. YE QQ, Zhou XG, Yang G, Xie WT, et al
    Correction to: Overcoming transfusion-refractory anemia: partial splenic embolization to facilitate orthopedic surgery in beta-thalassemia.
    Ann Hematol. 2026;105:165.
    PubMed    
    
    
    
40. CORDELLA S, Gilioli A, Pioli V, Messerotti A, et al
    Hemopoietic stem cell transplantation for infectious mononucleosis-related aplastic anemia.
    Ann Hematol. 2026;105:160.
    PubMed     Abstract available
    
    
    
41. WANG Y, Yuan X, Xiao W, Lu Y, et al
    Comparison of the diagnostic performance of machine learning algorithms for differentiating iron deficiency anemia and thalassemia.
    Ann Hematol. 2026;105:159.
    PubMed     Abstract available
    
    
    
42. HUANG L, Wei Z, Yang G, Liu L, et al
    Transforming the treatment of Alpha-Thalassemia: a single-center retrospective study on hematopoietic stem cell transplantation in transfusion-dependent pediatric patients.
    Ann Hematol. 2026;105:157.
    PubMed     Abstract available
    
    
    
43. ZHANG L, Yang J, Li X, Liu Y, et al
    A novel HBD gene mutation associated with normal-range hb A2 in beta-thalassemia carriers.
    Ann Hematol. 2026;105:151.
    PubMed     Abstract available
    
    
    February 2026
44. ESA E, Mohd Pauzy LH, Hashim H, Md Nor AN, et al
    Determination of mean corpuscular haemoglobin cut-off point for differentiating alpha plus and alpha zero thalassaemia in thalassaemia screening.
    Ann Hematol. 2026;105:146.
    PubMed     Abstract available
    
    
    
45. HASANI E, Naghinejad M, Kohkalani M, Mansoori Derakhshan S, et al
    A novel frameshift deletion in SLC25A38 and its role in mitochondrial dysfunction: A case study of sideroblastic anemia in a child from Iran.
    Ann Hematol. 2026;105:128.
    PubMed    
    
    
    
46. GUNDUZ E, Ulas T, Ozkalemkas F, Toprak SK, et al
    Assessment of characteristics and treatment patterns of adult patients with acquired aplastic anemia in Turkiye (PLANE-TR).
    Ann Hematol. 2026;105:130.
    PubMed     Abstract available
    
    
    
47. DE ALMEIDA BARROS VM, Silva-Pinto AC, Moura PG, Gualandro SFM, et al
    Risk of vaso-occlusive crisis requiring hospitalization in sickle cell disease patients in brazil: retrospective cohort study of real-world data.
    Ann Hematol. 2026;105:125.
    PubMed     Abstract available
    
    
    
48. BELISARIO AR, Ozahata MC, Moura ICG, Miranda C, et al
    Laboratory and genetic characteristic associated with gallbladder-related outcomes in sickle cell disease in Brazil: results from the REDS-III multicenter cohort study.
    Ann Hematol. 2026;105:115.
    PubMed     Abstract available
    
    
    
49. GUI Y, Chen W, Su Y, Qin C, et al
    Machine learning and AI-Assisted red blood cell morphology analysis for effective thalassemia screening.
    Ann Hematol. 2026;105:112.
    PubMed     Abstract available
    
    
    
50. YE QQ, Zhou XG, Yang G, Xie WT, et al
    Overcoming transfusion-refractory anemia: partial splenic embolization to facilitate orthopedic surgery in beta-thalassemia.
    Ann Hematol. 2026;105:101.
    PubMed     Abstract available
    
    
    
51. NRI-EZEDI CA, Efobi CC, Darbari D, Habib NB, et al
    Platelet-neutrophil ratio as a potential biomarker for stroke risk stratification in children and young adults with sickle cell anaemia in resource poor settings.
    Ann Hematol. 2026;105:92.
    PubMed     Abstract available
    
    
    
52. DELICOU S, Xydaki A, Kamposou V, Goga S, et al
    Epidemiological and comorbidity burden in transfusion-dependent patients with thalassemia and sickle cell disease in Greece.
    Ann Hematol. 2026;105:95.
    PubMed     Abstract available
    
    
    
53. MALAEB F, Mobarak N, Alshahrani D, Almanjomi F, et al
    Neurofibromatosis type I -related severe aplastic anemia: an unusual association with a complicated bone marrow transplantation course.
    Ann Hematol. 2026;105:83.
    PubMed     Abstract available
    
    
    
54. TAN Z, Hu J, Zhao Y, Hu H, et al
    Plasma exchange combined with anti-B-cell therapy enables comparable outcomes between DSA-positive and DSA-negative aplastic anemia after haplo-HSCT: a propensity-score-matched cohort study.
    Ann Hematol. 2026;105:73.
    PubMed     Abstract available
    
    
    
55. BAI Z, Hu J, Jin Y, Li X, et al
    Activated partial thromboplastin time prolongation without hemorrhagic dienhesis: a study of a chinese family coexisting with hereditary KNG1 p.Arg240 mutation and --SEA/alphaalpha genotype thalassemia.
    Ann Hematol. 2026;105:72.
    PubMed     Abstract available
    
    
    
56. GAMEEL AM, Abdelsattar S, Kasemy ZA, El-Hamid MEA, et al
    The impact of the expression signatures of LncRNAs HBBP1 and XIST on the diagnostic significance of patients with beta-Thalassemia.
    Ann Hematol. 2026;105:75.
    PubMed     Abstract available
    
    
    
57. KOMVILAISAK P, Laoaroon N, Paopongsawan P, Jirapradittha J, et al
    Many faces of non?deletional alpha?thalassaemia variants in neonate and early childhood.
    Ann Hematol. 2026;105:80.
    PubMed     Abstract available
    
    
    
58. SHAMAHMOOD MN, Meghdadi MR, Nasiri M, Yousefi MJ, et al
    Red blood cell alloimmunization in transfusion-dependent beta-thalassemia major patients in Eastern Iran.
    Ann Hematol. 2026;105:85.
    PubMed     Abstract available
    
    
    January 2026
59. WEN X, Xiao L, Li D, Liao M, et al
    Machine learning mortality prediction model for cyclosporine therapy in pediatric aplastic anemia.
    Ann Hematol. 2026;105:69.
    PubMed     Abstract available
    
    
    
60. GEORGE B, Ross CR, Damodar S, Seth T, et al
    A meta-analysis of immunosuppressive and Pharmacological therapies in aplastic anaemia with and without Indigenous equine antithymocyte globulin (eATG).
    Ann Hematol. 2026;105:52.
    PubMed     Abstract available
    
    
    
61. HALKES CJM, Koster EAS, Bogers EJM, Heubel-Moenen FCJI, et al
    Anti-thymocyte globulin-based treatment frequently leads to enduring treatment success in both old and young adult patients with aplastic anaemia: a real-world analysis from the Dutch aplastic anaemia registry.
    Ann Hematol. 2026;105:51.
    PubMed     Abstract available
    
    
    
62. IORI AP, De Vivo A, Di Bona E, Caocci G, et al
    Real life use of ravulizumab in Italian patients with paroxysmal nocturnal hemoglobinuria: evidence from the REACTION observational study.
    Ann Hematol. 2026;105:50.
    PubMed     Abstract available
    
    
    
63. ALLARD PN, Kulozik AE, Kunz JB
    Case series: a rare dominant form of beta-thalassemia successfully treated by luspatercept.
    Ann Hematol. 2026;105:45.
    PubMed     Abstract available
    
    
    
64. HU K, Cheng Y, Xiao G, Shen X, et al
    Mendelian randomization analysis of immune cell subsets and inflammatory cytokines in aplastic anaemia.
    Ann Hematol. 2026;105:36.
    PubMed     Abstract available
    
    
    
65. BISIOU S, Lobbes H, Palassin P, Allouchery M, et al
    Immune checkpoint inhibitor-induced pure red cell aplasia: a nationwide retrospective case series and literature review.
    Ann Hematol. 2026;105:38.
    PubMed     Abstract available
    
    
    
66. XING L, Yang W, Fan H, Li J, et al
    Cyclosporine related adverse events in aplastic anemia patients treated with immunosuppressive therapy.
    Ann Hematol. 2026;105:27.
    PubMed     Abstract available
    
    
    
67. JIA X, Zheng R, Hong Y, Ge H, et al
    Luspatercept for the treatment of transfusion-dependent non-severe aplastic anemia.
    Ann Hematol. 2026;105:6.
    PubMed    
    
    
    
68. OTHMANI M, Amri Y, Jouini Y, Ouali F, et al
    Vitamin D deficiency in sickle cell disease: a neglected comorbidity in Tunisia.
    Ann Hematol. 2026;105:2.
    PubMed     Abstract available
    
    
    December 2025
69. BENITO SF, Abio M, Bardon-Cancho EJ, Nieto JM, et al
    Importance of the 3'UTR region in globin synthesis: identification of two novel HBA1 mutations causing alpha-Thalassemia.
    Ann Hematol. 2025;104:6169-6174.
    PubMed     Abstract available
    
    
    
70. CHIBUIFE EC, Chisom Adaobi NE, Odini F, Deepika HD, et al
    Can platelet to neutrophil ratio (PNR) serve as a viable alternative tool for monitoring sickle cell disease patients on hydroxyurea in low income countries?
    Ann Hematol. 2025;104:6161-6168.
    PubMed     Abstract available
    
    
    
71. LIU HL, Huang WT
    Hemoglobin suresnes combined with alpha(0)-thalassemia: Diagnostic challenges and insights from trio-based whole exome sequencing.
    Ann Hematol. 2025;104:6391-6394.
    PubMed     Abstract available
    
    
    
72. YE C, Zhou X, Wei Y, Zhao Y, et al
    A direct multiplex isothermal amplification-reverse dot blot hybridization system for beta-thalassemia diagnosis.
    Ann Hematol. 2025;104:6147-6159.
    PubMed     Abstract available
    
    
    November 2025
73. GE Y, Yang Y, Luo Y, Xian L, et al
    Characterization and risk assessment of HbF elevation in non-thalassemia hematologic disease patients in Guangdong region.
    Ann Hematol. 2025;104:5647-5654.
    PubMed     Abstract available
    
    
    
74. FARES R, Bakr S, El-Hamid RGA, Abdelaleem OO, et al
    Circulating miR-145-5p and miR-133a-3p in pediatric sickle cell disease: biomarker potential for vaso-occlusive crises and disease activity.
    Ann Hematol. 2025;104:5625-5633.
    PubMed     Abstract available
    
    
    
75. FUREDER W, Granser S, Repa A, Farr A, et al
    Ravulizumab exposure in early pregnancy.
    Ann Hematol. 2025;104:6081-6084.
    PubMed     Abstract available
    
    
    October 2025
76. BOSQUES L, Modepalli S, Nagarajan A, Tang C, et al
    Codanin-1, defective in congenital dyserythropoietic anemia I (CDA-I), regulates erythroid differentiation.
    Ann Hematol. 2025 Oct 1. doi: 10.1007/s00277-025-06540.
    PubMed     Abstract available
    
    
    
77. WANG Z, Yu XH, Liang JL, Lai BR, et al
    Establishment of reference interval (RI) for G6PD/6PGD ratio in adults from Yangjiang, China.
    Ann Hematol. 2025;104:4959-4968.
    PubMed     Abstract available
    
    
    
78. KOTILA T, Aworanti O, Akunwata C, Ogundeji P, et al
    Haemoglobin variants in nigeria: real-world data from a point-of-care device.
    Ann Hematol. 2025;104:5055-5061.
    PubMed     Abstract available
    
    
    
79. NKYA S, Mahawi I, Shungu R, Nzunda C, et al
    Early-life clinical and hematological profiles: a comparative study of children with and without sickle cell disease in the first three years of life.
    Ann Hematol. 2025;104:4949-4957.
    PubMed     Abstract available
    
    
    
80. WU J, Wang L, Jin Z, Ren L, et al
    Epidemiological study of thalassemia in the Buyi population of Qiannan Prefecture, Guizhou Province, China based on third-generation sequencing.
    Ann Hematol. 2025;104:5037-5045.
    PubMed     Abstract available
    
    
    
81. KOFFI JFK, Botti RP, Ayemou R, N'dri AAC, et al
    Morbidity and mortality of sickle cell disease in Cote d'Ivoire.
    Ann Hematol. 2025;104:5019-5025.
    PubMed     Abstract available
    
    
    
82. WANG X, Ding Y, Huang Z, Huang J, et al
    The diagnosis and clinical characterization of -alpha3.7/--SEA thalassemia patients: two cases report.
    Ann Hematol. 2025;104:5501-5506.
    PubMed     Abstract available
    
    
    
83. WIRAHMADI A, Rahmartani LD, Wahidiyat PA
    Revisiting hepatitis B vaccination in children with transfusion-dependent thalassemia.
    Ann Hematol. 2025;104:5011-5017.
    PubMed     Abstract available
    
    
    September 2025
84. YANG C, Huang J, Yang K, Wei C, et al
    Haploidentical hematopoietic stem cell transplantation for the treatment of congenital dyserythropoietic anemia combined with thalassemia: a report of two cases.
    Ann Hematol. 2025 Sep 26. doi: 10.1007/s00277-025-06615.
    PubMed     Abstract available
    
    
    
85. BIRSIN Z, Salihoglu A, Tokdil KO, Pirdal BZ, et al
    Is splenectomy one of the contributory factors to pulmonary hypertension? An analysis of splenectomized hemolytic anemia and immune thrombocytopenia patients.
    Ann Hematol. 2025 Sep 9. doi: 10.1007/s00277-025-06583.
    PubMed     Abstract available
    
    
    
86. NAGEL SN, Brintrup J, Ghannam Y, Stallmach A, et al
    Combined heterozygosity for the highly unstable variant hemoglobin Taybe, and alpha-thalassemia as a rare cause of hemolytic anemia.
    Ann Hematol. 2025 Sep 9. doi: 10.1007/s00277-025-06578.
    PubMed    
    
    
    
87. MAKALO L, Manka M, Perez OR, Joof S, et al
    Severity patterns and predictors of sickle cell anaemia among Gambian children: A cross-sectional analysis.
    Ann Hematol. 2025;104:4429-4436.
    PubMed     Abstract available
    
    
    
88. GONG Y, Chai X, Liu X, Zhang Y, et al
    Comprehensive analysis of the clinical feature, myeloid neoplasm-related gene mutation profiles and T cell diversity acquired pure red cell aplasia.
    Ann Hematol. 2025;104:4411-4427.
    PubMed     Abstract available
    
    
    
89. ABBAS S, Khan MO, Arif A, Majid H, et al
    Framework for the comprehensive screening for endocrine disorders in patients with transfusion-dependent thalassemia in low-resource settings.
    Ann Hematol. 2025;104:4391-4409.
    PubMed     Abstract available
    
    
    
90. YU L, Xu G, Chen Z, Lin K, et al
    Genetic analysis of thalassemia in putian: comparative insights into mutation spectra with other global regions.
    Ann Hematol. 2025;104:4465-4476.
    PubMed     Abstract available
    
    
    
91. WEI R, Qiu D, Zeng X
    Genetic biomarkers and crucial cell subsets of iron metabolism in Beta-Thalassemia: insights from bioinformatics and experimental validation.
    Ann Hematol. 2025;104:4369-4384.
    PubMed     Abstract available
    
    
    
92. BROGHAMMER S, Gagesch M, Wieczorek M, Kressig RW, et al
    Hemoglobin levels and frailty status in generally healthy and active community-dwelling adults age 70 years and older in the three-year DO-HEALTH study.
    Ann Hematol. 2025;104:4437-4445.
    PubMed     Abstract available
    
    
    
93. BEZIRGIANNIDOU Z, Stamatiou I, Theodoridis TM, Kontekaki E, et al
    Ravulizumab stabilizes life-threating intravascular hemolysis following delayed hemolytic transfusion reaction due to alloantibodies anti-e and anti-Jka: the first successful administration.
    Ann Hematol. 2025;104:4849-4854.
    PubMed     Abstract available
    
    
    
94. D'ADDIO A, Rondoni M, Salvucci M, Marconi G, et al
    PNH clones prevalence study in ph-negative myeloproliferative neoplasms: a multicenter Italian study.
    Ann Hematol. 2025;104:4487-4494.
    PubMed     Abstract available
    
    
    
95. HUANG L, Li M, Niu T, Chang H, et al
    Anti-plasma cell therapy in patients with monoclonal gammopathy-associated refractory pure red cell aplasia: A report of three cases and literature review.
    Ann Hematol. 2025;104:4837-4841.
    PubMed     Abstract available
    
    
    
96. ALKINDI S, Al Subhi A, Pathare A
    Rapid withdrawal of voxelotor can precipitate sickle cell disease related crisis.
    Ann Hematol. 2025;104:4855-4857.
    PubMed     Abstract available
    
    
    August 2025
97. ZHANG X, Xie J, Wang H, Li J, et al
    Analysis of fecal microbiome in Chinese patients with non-severe aplastic anemia.
    Ann Hematol. 2025 Aug 19. doi: 10.1007/s00277-025-06459.
    PubMed     Abstract available
    
    
    
98. YE L, Zhang L, Zhang D, Zhao X, et al
    Somatic mutations and the efficacy of immunosuppressive therapy in severe/very severe aplastic anemia and transfusion-dependent nonsevere aplastic anemia.
    Ann Hematol. 2025 Aug 7. doi: 10.1007/s00277-025-06393.
    PubMed     Abstract available
    
    
    
99. SHI L, Yan X, Xia Y, Zhao Y, et al
    Beyond transfusions and transplants: genomic innovations rewriting the narrative of thalassemia.
    Ann Hematol. 2025;104:3963-3980.
    PubMed     Abstract available
    
    
    
100. OZAHATA MC, Gomes I, Oliveira BA, Park M, et al
     Genetic modifiers of frequent vaso-occlusive hospitalizations among individuals with sickle cell disease (SCD).
     Ann Hematol. 2025;104:4029-4035.
     PubMed     Abstract available
     
     
     
101. LI H, Gu Y, Zhao X, Ding G, et al
     Comparative longitudinal analysis of pulmonary function post-pediatric Allo-HSCT: benign vs. malignant diseases and early predictors.
     Ann Hematol. 2025;104:4201-4211.
     PubMed     Abstract available
     
     
     
102. WARNCKE K, Nero A, Sarode R, Adkins BD, et al
     Hyperhemolysis in a sickle cell disease patient in pregnancy.
     Ann Hematol. 2025;104:4245-4249.
     PubMed     Abstract available
     
     
     
103. PEDERSEN TH, Tjonnfjord E, Korkama ES, Vikman M, et al
     The incidence of paroxysmal nocturnal hemoglobinuria cell clones in the Nordic countries.
     Ann Hematol. 2025;104:4277-4283.
     PubMed     Abstract available
     
     
     
104. NIKOLAIDIS CG, Gyriki D, Gogos DG, Stavropoulou E, et al
     Sickle cell beta-thalassemia diagnosed at age 40: a case report.
     Ann Hematol. 2025;104:4229-4236.
     PubMed     Abstract available
     
     
     
105. WANG Y, Liu T, Wang W, Li Y, et al
     Three novel heterozygous ANK1 loss-of-function variants cause hereditary spherocytosis in Chinese families.
     Ann Hematol. 2025;104:4045-4056.
     PubMed     Abstract available
     
     
     July 2025
106. JANG JH, Mitani K, Tomiyama Y, Miyazaki K, et al
     Predictive factors of romiplostim response in patients with refractory aplastic anemia: data from two clinical trials.
     Ann Hematol. 2025 Jul 1. doi: 10.1007/s00277-025-06337.
     PubMed     Abstract available
     
     
     
107. CHEN R, Zhang R, He X, Zhang Q, et al
     Factors influencing prenatal diagnosis of deletional hemoglobin H disease in thalassemia prevention and control program, Southern China.
     Ann Hematol. 2025;104:3567-3574.
     PubMed     Abstract available
     
     
     
108. UEDA Y, Obara N, Ueno S, Sakurai M, et al
     Treatment burden in patients with paroxysmal nocturnal hemoglobinuria: an in-depth interview survey.
     Ann Hematol. 2025;104:3575-3584.
     PubMed     Abstract available
     
     
     
109. LIU H, Du Y, Yang Y, Cui D, et al
     Identification of a novel complex variant in a patient involving the alpha-globin gene cluster by third-generation sequencing.
     Ann Hematol. 2025;104:3619-3629.
     PubMed     Abstract available
     
     
     
110. LI Y, Jiang H, Luo L, Mei H, et al
     Immunotherapy-associated hemostatic abnormalities: bleeding and thrombotic complications.
     Ann Hematol. 2025;104:3537-3551.
     PubMed     Abstract available
     
     
     
111. ENGOLE YM, Makulo JRR, Bukabau JB, Nlandu YM, et al
     Genotype-dependent albuminuria in adult sickle cell disease in Kinshasa.
     Ann Hematol. 2025;104:3585-3595.
     PubMed     Abstract available
     
     
     
112. ZHU G, Ren Y, Wang L, Wang S, et al
     Assessing serum thrombopoietin for enhanced diagnosis of ITP, AA, and MDS using machine learning: A retrospective cohort study.
     Ann Hematol. 2025;104:3631-3645.
     PubMed     Abstract available
     
     
     
113. HOSOKAWA K, Imi T, Yokota T, Tada Y, et al
     High-dose romiplostim for donor-type aplasia.
     Ann Hematol. 2025;104:3863-3867.
     PubMed     Abstract available
     
     
     June 2025
114. ZHANG S, Ji Q, Gao L, Wang Q, et al
     Efficacy and safety of rabbit ATLG and ATG in allogeneic hematopoietic stem cell transplantation for children with acquired severe aplastic anemia.
     Ann Hematol. 2025 Jun 19. doi: 10.1007/s00277-025-06461.
     PubMed     Abstract available
     
     
     
115. CHAIPOKAM J, Rojnuckarin P
     Good response to oxymetholone in adult aplastic anemia.
     Ann Hematol. 2025 Jun 14. doi: 10.1007/s00277-025-06460.
     PubMed     Abstract available
     
     
     
116. AMRI Y, Fredj SH, Dabboubi R, Othmani R, et al
     Revealing silent alpha-thalassemia: characterization of novel HBA1 deletion and missense mutation in Tunisian families.
     Ann Hematol. 2025;104:3173-3182.
     PubMed     Abstract available
     
     
     
117. LIN MH, Wang YJ, Zhang YY, Cheng YF, et al
     The outcomes of second haploidentical donor transplantation for graft failure in patients with severe aplastic anaemia.
     Ann Hematol. 2025;104:3469-3476.
     PubMed     Abstract available
     
     
     
118. PANSE J, Han B, Cermak J, Gonzalez Fernandez FA, et al
     Patient-reported outcomes in patients with paroxysmal nocturnal hemoglobinuria treated with crovalimab and approved C5 inhibitors in the phase III COMMODORE 2 and 1 studies.
     Ann Hematol. 2025;104:3199-3212.
     PubMed     Abstract available
     
     
     
119. YOUSSRY I, El-Ghamrawy M, Youness ER, Mohamed NA, et al
     Zinc level and its impact on the phenotype of sickle cell disease.
     Ann Hematol. 2025;104:3213-3221.
     PubMed     Abstract available
     
     
     May 2025
120. PARK S, Kim HK
     Epidemiologic sequential analysis of pure red blood cell aplasia and T-cell large granular lymphocyte leukemia in Korea.
     Ann Hematol. 2025 May 22. doi: 10.1007/s00277-025-06406.
     PubMed     Abstract available
     
     
     
121. EFOBI C, Ukpai N, Eze OE, Basil B, et al
     Platelet-to-Neutrophil ratio as a predictor of risk of complications in sickle cell disease: a valuable insight for resource-limited settings.
     Ann Hematol. 2025;104:2663-2669.
     PubMed     Abstract available
     
     
     
122. MAHABHOL C, Yothindamrongkul L, Nuntanajaroenkul N, Nawasod P, et al
     Genetic polymorphism of novel SNP rs5006884 in OR51B6 and SNP rs4499252 in AHSP among transfusion-dependent and non-transfusion-dependent beta-thalassemia/Hb E patients in Thailand: a multivariate analysis of clinical and genetic polymorphism.
     Ann Hematol. 2025;104:2653-2661.
     PubMed     Abstract available
     
     
     
123. KWON YD, Hong KT, Lee J, Sunwoo Y, et al
     Clinical usefulness of next-generation sequencing-based target gene sequencing in diagnosis of inherited bone marrow failure syndrome.
     Ann Hematol. 2025;104:2693-2706.
     PubMed     Abstract available
     
     
     
124. AN N, Bian K, Li C
     Alemtuzumab for haematological malignancies.
     Ann Hematol. 2025;104:2593-2603.
     PubMed     Abstract available
     
     
     April 2025
125. TAYLOR KJ, Singer S, Langemeijer S, Kelly RJ, et al
     What are the most important quality of life domains for patients with aplastic anemia and paroxysmal nocturnal hemoglobinuria?
     Ann Hematol. 2025 Apr 29. doi: 10.1007/s00277-025-06377.
     PubMed    
     
     
     
126. LIU X, Chai X, Yu Q, Wang W, et al
     Clinical features and outcomes in large granular lymphocyte leukemia - associated pure red cell aplasia with STAT3 mutation.
     Ann Hematol. 2025 Apr 23. doi: 10.1007/s00277-025-06371.
     PubMed     Abstract available
     
     
     
127. CHEN T, Song J, Xing L, Chen J, et al
     From severe aplastic anemia with TERT variant to Wilson disease - associations or not.
     Ann Hematol. 2025 Apr 21. doi: 10.1007/s00277-025-06370.
     PubMed     Abstract available
     
     
     
128. LI J, Shi Y, Zhang B, Yang W, et al
     The efficacy of immunosuppressive therapy with or without thrombopoietin receptor agonist in elderly patients with severe aplastic anemia.
     Ann Hematol. 2025 Apr 7. doi: 10.1007/s00277-025-06335.
     PubMed     Abstract available
     
     
     
129. RAMESH M, Fakhari-Tehrani Y, Deenadayalan V, Padhi P, et al
     Impact of protein-energy malnutrition on outcomes of patients with sickle cell disease: an analysis of the National inpatient sample.
     Ann Hematol. 2025;104:2171-2177.
     PubMed     Abstract available
     
     
     
130. MANNING JE, Ciantar E, Griffin M, Kelly RJ, et al
     Paroxysmal nocturnal haemoglobinuria in pregnancy-a systematic review with meta analysis.
     Ann Hematol. 2025;104:2517-2525.
     PubMed     Abstract available
     
     
     
131. AL-AWADHI A, Alwehaidah MS, Al-Sabaan K, Al-Ajmi N, et al
     Assessment of ferritin and hepcidin levels in splenectomised and non-splenectomised beta-thalassemia major patients and exploring a potential correlation with von Willebrand factor and ADAMTS-13.
     Ann Hematol. 2025;104:2229-2238.
     PubMed     Abstract available
     
     
     
132. YUSUP M, He G, Qin Y, Tuerxun N, et al
     Efficacy and influencing factors of immunosuppressive therapy for pure red cell aplasia: meta-analysis and systematic review.
     Ann Hematol. 2025;104:2189-2206.
     PubMed     Abstract available
     
     
     
133. RODRIGUEZ NG, Franciss G, Perez E, Maryam Z, et al
     Understanding the role of asthma in acute chest syndrome: a comparative analysis of patients with and without asthma.
     Ann Hematol. 2025;104:2179-2187.
     PubMed     Abstract available
     
     
     
134. JIANG F, Wu J, Yang M, Chen X, et al
     An unusual transfusion-dependent hemoglobin H disease caused by a novel complex inverted duplication involving the alpha-globin regulatory elements and alpha-thalassemia--SEA deletion.
     Ann Hematol. 2025;104:2529-2535.
     PubMed     Abstract available
     
     
     March 2025
135. STEMPEL JM, Wang R, Lee AI, Zeidan AM, et al
     Initial management of patients with acquired aplastic anemia in the United States: results from a large national claims database.
     Ann Hematol. 2025 Mar 19. doi: 10.1007/s00277-025-06307.
     PubMed     Abstract available
     
     
     
136. ROMANELLO KS, da Silva JPMO, Torres FF, Teixeira KKL, et al
     Unraveling the multifaceted roles of peroxiredoxins in sickle cell anemia: implications in redox and inflammation adaptations.
     Ann Hematol. 2025 Mar 14. doi: 10.1007/s00277-025-06294.
     PubMed     Abstract available
     
     
     
137. LIU T, Fillbrunn M, Zhang S, Chen J, et al
     Treatment patterns and healthcare resource utilization in ruxolitinib-treated patients with myelofibrosis with and without anemia: a real-world analysis.
     Ann Hematol. 2025 Mar 12. doi: 10.1007/s00277-025-06279.
     PubMed     Abstract available
     
     
     
138. REKAYA S, Ben Fraj I, Hamdi R, Ben Taieb A, et al
     Sideroblastic anemia in children: challenges in diagnosis and management in three cases.
     Ann Hematol. 2025 Mar 5. doi: 10.1007/s00277-025-06266.
     PubMed     Abstract available
     
     
     
139. KAWAKAMI T, Kawakami F, Matsuzawa S, Yamane T, et al
     Mutational heterogeneities in STAT3 and clonal hematopoiesis-related genes in acquired pure red cell aplasia.
     Ann Hematol. 2025;104:1471-1479.
     PubMed     Abstract available
     
     
     
140. KEESARI PR, Vegivinti CTR, Rajamanuri M, Mustafa A, et al
     Racial disparities in cardiovascular manifestations among patients with sickle cell trait: analysis of national inpatient sample data (2016-2020).
     Ann Hematol. 2025;104:1501-1506.
     PubMed     Abstract available
     
     
     
141. LAI D, Chen D, Chen X, Zhou R, et al
     Effect of major ABO blood group mismatched HSCT on blood transfusion and clinical outcomes in AA patients.
     Ann Hematol. 2025;104:1931-1947.
     PubMed     Abstract available
     
     
     
142. KARGAR M, Kaydani GA, Keikhaei B, Saki N, et al
     Association between HLA-DRB1*04, HLA-DQB1*03, and HLA-DQB1*06 with alloimmunization in transfusion-dependent patients with thalassemia: the first case-control study in Iran.
     Ann Hematol. 2025;104:1493-1499.
     PubMed     Abstract available
     
     
     
143. BODE AL, Borja-Montes OF, Quazi MA, Mumtaz A, et al
     Sickle cell disease and opioid overdose outcomes in the United States: a nationwide analysis.
     Ann Hematol. 2025;104:1551-1561.
     PubMed     Abstract available
     
     
     
144. LI Y, Feng Y, Wei Y, Huang J, et al
     The impact of various types of alpha-thalassemia on perinatal complications and pregnancy outcomes in pregnant women.
     Ann Hematol. 2025;104:1541-1550.
     PubMed     Abstract available
     
     
     
145. HUANG L, Zhang Q, Ye Y, Long Y, et al
     Rapid detection of genetic modifiers of beta-thalassemia based on MALDI-TOF MS.
     Ann Hematol. 2025;104:1481-1492.
     PubMed     Abstract available
     
     
     
146. SCHNEDL WJ, Leixner G, Voill-Glaninger A, Michaelis S, et al
     Combined heterozygosity for hemoglobin Pakse, alpha-thalassemia and for hemoglobin E, beta- thalassemia ? first appearance in Europe.
     Ann Hematol. 2025;104:2059-2064.
     PubMed     Abstract available
     
     
     
147. ALHARBI M, Bawek S, Lund I, Glenn ST, et al
     Rare case of pure red cell aplasia secondary to smoldering multiple myeloma successfully treated with daratumumab - case report and review of the literature.
     Ann Hematol. 2025;104:2027-2034.
     PubMed     Abstract available
     
     
     
148. TAN Z, Zhang X, Feng J, Zhao Y, et al
     Hematopoietic stem cell transplantation and immunosuppressive therapy: implications of clonal haematopoiesis.
     Ann Hematol. 2025;104:1877-1886.
     PubMed     Abstract available
     
     
     February 2025
149. CHEN L, Wei X, Zheng C, Liu X, et al
     Novel AK-1 gene variants combined with thalassemia causing rare hereditary non-spherocytic hemolytic anemia in a Chinese family.
     Ann Hematol. 2025 Feb 28. doi: 10.1007/s00277-025-06289.
     PubMed     Abstract available
     
     
     
150. YAN Q, Zhang Y, Wei L, Liu X, et al
     Assessment of anemia recovery using peripheral blood smears by deep semi-supervised learning.
     Ann Hematol. 2025 Feb 21. doi: 10.1007/s00277-025-06254.
     PubMed     Abstract available
     
     
     
151. LIU A, Jacobs-McFarlane C, Sebastiani P, Glassberg J, et al
     Plasma free hemoglobin is associated with LDH, AST, total bilirubin, reticulocyte count, and the hemolysis score in patients with sickle cell anemia.
     Ann Hematol. 2025 Feb 19. doi: 10.1007/s00277-025-06253.
     PubMed     Abstract available
     
     
     
152. CHEN X, Yu Q, Qin C, Zhang Y, et al
     Combining immunosuppressive therapy with low dosage eltrombopag in Chinese patients with severe aplastic anemia: mild aggravation of hepatic injury.
     Ann Hematol. 2025 Feb 5. doi: 10.1007/s00277-025-06210.
     PubMed     Abstract available
     
     
     
153. AMMAR M, Kmiha S, Maalej M, Felhi R, et al
     Identification of a novel truncated pathogenic variant in PUS1 gene in two siblings of consanguineous Tunisian family: intrafamilial phenotypic variability related to mtDNA copy number.
     Ann Hematol. 2025;104:943-952.
     PubMed     Abstract available
     
     
     
154. WU T, Ren Z, Liu X, Xing Z, et al
     Systematic identification and validation of ceRNA-driven regulatory mechanisms in pediatric beta-Thalassemia major.
     Ann Hematol. 2025;104:963-972.
     PubMed     Abstract available
     
     
     
155. ARLET JB, Bernaudin F, Deme-Ly I, Coulibaly B, et al
     Use of hydroxyurea in French-speaking Sub-Saharan Africa.
     Ann Hematol. 2025;104:937-941.
     PubMed     Abstract available
     
     
     
156. LIU Y, Liu M, He X, Yang L, et al
     Molecular landscape of CD8(+) T cells in pure red cell aplasia.
     Ann Hematol. 2025;104:953-961.
     PubMed     Abstract available
     
     
     
157. MAHADEVIA H, Ponvilawan B, Madan U, Sharma P, et al
     A review on disease modifying pharmacologic therapies for sickle cell disease.
     Ann Hematol. 2025;104:881-893.
     PubMed     Abstract available
     
     
     
158. XING L, Liang W, Li Y, Xiao J, et al
     Concurrent inhibited erythropoiesis in a case of VEXAS syndrome.
     Ann Hematol. 2025;104:1255-1258.
     PubMed     Abstract available
     
     
     
159. RIEDL J, Pfeilstocker M, Farr A, Hausler G, et al
     Management of paroxysmal nocturnal hemoglobinuria with low-level hemolysis in pregnancy- a report of two cases.
     Ann Hematol. 2025;104:1249-1253.
     PubMed     Abstract available
     
     
     
160. GOLDSCHMIDT V, Apodaca EI, Galvez KM, Wannesson B, et al
     Clinical characteristics and management of paroxysmal nocturnal haemoglobinuria in Latin America: a narrative review.
     Ann Hematol. 2025;104:867-879.
     PubMed     Abstract available
     
     
     January 2025
161. YANG K, Li Q, Zhuang X, Ma H, et al
     A retrospective analysis of autoimmune hemolytic anemia after allogeneic hematopoietic stem cell transplantation for transfusion-dependent beta-thalassemia: focus on T and B lymphocyte reconstitution.
     Ann Hematol. 2025 Jan 3. doi: 10.1007/s00277-024-06157.
     PubMed     Abstract available
     
     
     
162. KULASEKARARAJ A, Brodsky R, Schrezenmeier H, Griffin M, et al
     Ravulizumab demonstrates long-term efficacy, safety and favorable patient survival in patients with paroxysmal nocturnal hemoglobinuria.
     Ann Hematol. 2025;104:81-94.
     PubMed     Abstract available
     
     
     
163. ZHUANG J, Huang N, Zheng Y, Zhang N, et al
     First clinical and pedigree study of rare HBB: c.316-90 A > G variant in beta-globin gene in Chinese population using third-generation sequencing.
     Ann Hematol. 2025;104:75-80.
     PubMed     Abstract available
     
     
     December 2024
164. JANG T, Burnside RD, Chaffin J, Seifert R, et al
     Severe aplastic anemia with acquired X chromosome clonality as a sole abnormality.
     Ann Hematol. 2024 Dec 31. doi: 10.1007/s00277-024-06166.
     PubMed     Abstract available
     
     
     
165. GAO M, Huang X, Gao S, Wang S, et al
     Similar outcomes between HLA-haploid and matched sibling donor hematopoietic stem cell transplantation: a multicenter, retrospective study and severe aplastic anemia transplant-specific prognostic scoring system.
     Ann Hematol. 2024 Dec 12. doi: 10.1007/s00277-024-06051.
     PubMed     Abstract available
     
     
     
166. PINES M, Kleinert D, Thomas C, Mensah C, et al
     Real-world experience with iron chelation therapy in transfusion-dependent thalassemia: impact of the oral chelators' era.
     Ann Hematol. 2024;103:5229-5234.
     PubMed     Abstract available
     
     
     
167. DAWUDI Y, Azoyan L, Bonjour M, Steichen O, et al
     COVID-19 outcomes among patients with sickle cell disease or sickle cell trait compared to the general population: a systematic review and meta-analyses.
     Ann Hematol. 2024;103:5071-5083.
     PubMed     Abstract available
     
     
     
168. DINGLI D, Rizio AA, Broderick L, LaGasse K, et al
     Health-related quality of life and symptom-specific functional impairment among patients treated with parenterally administered complement inhibitors for paroxysmal nocturnal hemoglobinuria.
     Ann Hematol. 2024;103:5213-5227.
     PubMed     Abstract available
     
     
     
169. FAN L, Cao L, Luo Y, Gao F, et al
     Roxadustat combined with immunosuppressants for treatment of pure red cell aplasia with kidney injury.
     Ann Hematol. 2024;103:5925-5927.
     PubMed     Abstract available
     
     
     
170. MOTTA I, Delbini P, Scaramellini N, Ghiandai V, et al
     Enzyme replacement therapy improves erythropoiesis and iron dysregulation in Gaucher disease.
     Ann Hematol. 2024;103:5113-5121.
     PubMed     Abstract available
     
     
     
171. GUO X, Lin S, Zhang X, Li M, et al
     Integrated metabolomic and microbiome analysis identifies Cupriavidus metallidurans as a potential therapeutic target for beta-thalassemia.
     Ann Hematol. 2024;103:5169-5179.
     PubMed     Abstract available
     
     
     November 2024
172. LOH JB, Ross JM, Musallam KM, Kuo KHM, et al
     Trans-acting genetic modifiers of clinical severity in heterozygous beta-Thalassemia trait.
     Ann Hematol. 2024;103:4437-4447.
     PubMed     Abstract available
     
     
     
173. DE SANTIS M, Tonutti A, Motta F, Todisco G, et al
     Approaches for the diagnosis and treatment of VEXAS syndrome: the importance of clinical suspicion and the use of methotrexate.
     Ann Hematol. 2024;103:4789-4791.
     PubMed     Abstract available
     
     
     October 2024
174. CAHUAPAZA-GUTIERREZ NL
     Aplastic Anemia in the light of the COVID-19 pandemic: infection, vaccination, and pathophysiologic mechanisms.
     Ann Hematol. 2024 Oct 23. doi: 10.1007/s00277-024-06052.
     PubMed     Abstract available
     
     
     
175. DONGERDIYE R, Kedar PS, Saptarshi A, Sampagar A, et al
     Non-syndromic congenital sideroblastic anaemia; phenotype, and genotype of 15 Indian patients.
     Ann Hematol. 2024;103:3987-3998.
     PubMed     Abstract available
     
     
     
176. ZHANG M, Liu M, Yang L, Liu Y, et al
     Increased ferroptosis of erythrocytes is associated with myelodysplastic syndromes.
     Ann Hematol. 2024;103:4009-4020.
     PubMed     Abstract available
     
     
     September 2024
177. CHEN WT, Wang SW, Huang Y, Tang RM, et al
     The effect of hetrombopag combined with conventional treatment on immune function and quality of life in patients with severe aplastic anemia.
     Ann Hematol. 2024 Sep 5. doi: 10.1007/s00277-024-05964.
     PubMed     Abstract available
     
     
     
178. EBEID FSE, Aly NH, Shaheen NM, Abdellatif SMA, et al
     Safety and efficacy of L-Glutamine in reducing the frequency of acute complications among patients with sickle cell disease: A randomized controlled study.
     Ann Hematol. 2024;103:3493-3506.
     PubMed     Abstract available
     
     
     
179. EZZAT EM, Bakr S, Golam RM, Abdelgyed BA, et al
     Adipocyte fatty acid-binding protein (FABP4) as a potential biomarker for predicting metabolically driven low-grade and organ damage in thalassemia syndromes.
     Ann Hematol. 2024;103:3473-3482.
     PubMed     Abstract available
     
     
     
180. JAJODIA E, Menghani H, Arora N, Jitani A, et al
     De-novo ATR-16 syndrome associated with inherited hemoglobin Evanston causing HbH phenotype: a rare occurrence.
     Ann Hematol. 2024;103:3805-3810.
     PubMed     Abstract available
     
     
     
181. PATSOURAKOS D, Aggeli C, Dimitroglou Y, Delicou S, et al
     Speckle tracking echocardiography and beta-thalassemia major. A systematic review.
     Ann Hematol. 2024;103:3335-3356.
     PubMed     Abstract available
     
     
     August 2024
182. SHEN S, Hu Q, Yang C, Jiang Z, et al
     Adding hetrombopag to cyclosporine a improved response of patients with newly diagnosed transfusion-dependent non-severe aplastic anemia.
     Ann Hematol. 2024 Aug 23. doi: 10.1007/s00277-024-05941.
     PubMed    
     
     
     
183. LI X, Shangguan X, Wang H, Wang Q, et al
     Comparison of efficacy of eltrombopag combined with immunosuppression in the treatment of severe aplastic anemia and very severe aplastic anemia: real-world data and evidence.
     Ann Hematol. 2024 Aug 1. doi: 10.1007/s00277-024-05910.
     PubMed     Abstract available
     
     
     
184. IQBAL N, Meghani MA, Khalid W, Ansari AH, et al
     Transcobalamin deficiency - a rare genetic defect in transportation of cobalamin; case report.
     Ann Hematol. 2024;103:3243-3246.
     PubMed     Abstract available
     
     
     
185. FUREDER W, Valent P
     Stable responses to danicopan as add-on to ravulizumab in two patients with paroxysmal nocturnal hemoglobinuria.
     Ann Hematol. 2024;103:3235-3238.
     PubMed    
     
     
     
186. MARCO SANCHEZ JM, Bardon Cancho EJ, Beneitez D, Payan-Pernia S, et al
     Haemoglobinopathies and other rare anemias in Spain: ten years of a nationwide registry (REHem-AR).
     Ann Hematol. 2024;103:2743-2755.
     PubMed     Abstract available
     
     
     
187. YANG J, Shi X, Liu X, Qiao X, et al
     STK10 mutations block erythropoiesis in acquired pure red cell aplasia via impairing ribosome biogenesis.
     Ann Hematol. 2024;103:2711-2720.
     PubMed     Abstract available
     
     
     
188. BHANGU G, Uminski K, Roessner C, Goodyear D, et al
     Dry gangrene in a patient with sickle cell disease on hydroxyurea: a case report.
     Ann Hematol. 2024;103:3277-3279.
     PubMed    
     
     
     
189. LI J, Lv A, Chen M, Xu L, et al
     Activating transcription factor 4 in erythroid development and beta -thalassemia: a powerful regulator with therapeutic potential.
     Ann Hematol. 2024;103:2659-2670.
     PubMed     Abstract available
     
     
     
190. YOUSSRY I, Ayad N
     Sickle cell disease: combination new therapies vs. CRISPR-Cas9 potential and challenges - review article.
     Ann Hematol. 2024;103:2613-2619.
     PubMed     Abstract available
     
     
     
191. KIRTHAN JPA, Somannavar MS
     Pathophysiology and management of iron deficiency anaemia in pregnancy: a review.
     Ann Hematol. 2024;103:2637-2646.
     PubMed     Abstract available
     
     
     July 2024
192. MUSALLAM KM, Barella S, Origa R, Ferrero GB, et al
     Revisiting iron overload status and change thresholds as predictors of mortality in transfusion-dependent beta-thalassemia: a 10-year cohort study.
     Ann Hematol. 2024;103:2283-2297.
     PubMed     Abstract available
     
     
     
193. TER AVEST M, Langemeijer SMC, Blijlevens NMA, van de Kar NCAJ, et al
     Development of a target concentration intervention to individualize paroxysmal nocturnal hemoglobinuria treatment with pegcetacoplan.
     Ann Hematol. 2024;103:2267-2272.
     PubMed     Abstract available
     
     
     June 2024
194. GONG Y, Li Y, Chen X, Yang H, et al
     Refractory pure red cell aplasia associated with T-cell large granular lymphocyte leukemia treated by ruxolitinib.
     Ann Hematol. 2024 Jun 27. doi: 10.1007/s00277-024-05856.
     PubMed     Abstract available
     
     
     
195. WANG L, Fang L, Shi H, Liu Y, et al
     Treatment of myelofibrosis with refractory anemia with luspatercept: a multicenter Chinese study.
     Ann Hematol. 2024 Jun 22. doi: 10.1007/s00277-024-05847.
     PubMed     Abstract available
     
     
     
196. KANTER J, Ataga KI, Bhasin N, Guarino S, et al
     Expert consensus on the management of infusion-related reactions (IRRs) in patients with sickle cell disease (SCD) receiving crizanlizumab: a RAND/UCLA modified Delphi panel.
     Ann Hematol. 2024;103:1909-1917.
     PubMed     Abstract available
     
     
     
197. ZHANG Z, Hu Q, Yang C, Chen M, et al
     Comparison of human leukocyte antigen in patients with paroxysmal nocturnal hemoglobinuria of different clone sizes.
     Ann Hematol. 2024;103:1897-1907.
     PubMed     Abstract available
     
     
     
198. MELONI A, Pistoia L, Ricchi P, Bagnato S, et al
     Impact of genotype on multi-organ iron and complications in patients with non-transfusion-dependent beta-thalassemia intermedia.
     Ann Hematol. 2024;103:1887-1896.
     PubMed     Abstract available
     
     
     
199. YANG L, Niu H, Zhang T, Cao Q, et al
     A nomogram model for predicting the efficacy of cyclosporine in patients with pure red cell aplasia.
     Ann Hematol. 2024;103:1877-1885.
     PubMed     Abstract available
     
     
     
200. ALAYOUBI AM, Khawaji ZY, Mohammed MA, Mercier FE, et al
     CRISPR-Cas9 system: a novel and promising era of genotherapy for beta-hemoglobinopathies, hematological malignancy, and hemophilia.
     Ann Hematol. 2024;103:1805-1817.
     PubMed     Abstract available
     
     
     May 2024
201. SHI Y, Zhao Y, Liang W, Zhang B, et al
     A preliminary study of roxadustat in the treatment of aplastic anemia patients with inadequate erythroid responses.
     Ann Hematol. 2024 May 22. doi: 10.1007/s00277-024-05799.
     PubMed     Abstract available
     
     
     
202. NAKAMURA Y, Zaimoku Y, Yamaguchi H, Yamazaki H, et al
     Significance of absolute neutrophil count before allogeneic hematopoietic stem cell transplantation in adult patients with aplastic anemia.
     Ann Hematol. 2024 May 16. doi: 10.1007/s00277-024-05800.
     PubMed     Abstract available
     
     
     
203. BARDON-CANCHO EJ, Marco-Sanchez JM, Beneitez-Pastor D, Payan-Pernia S, et al
     Spanish registry of hemoglobinopathies and rare anemias (REHem-AR): demographics, complications, and management of patients with beta-thalassemia.
     Ann Hematol. 2024;103:1525-1539.
     PubMed     Abstract available
     
     
     
204. AL-KURAISHY HM, Mazhar Ashour MH, Saad HM, Batiha GE, et al
     COVID-19 and beta-thalassemia: in lieu of evidence and vague nexus.
     Ann Hematol. 2024;103:1423-1433.
     PubMed     Abstract available
     
     
     April 2024
205. HU M, Li J, Liu R, Zhang Z, et al
     Unrelated umbilical cord blood transplantation with low-dose anti-thymocyte globulin for children with severe aplastic anemia: A case series.
     Ann Hematol. 2024 Apr 24. doi: 10.1007/s00277-024-05756.
     PubMed     Abstract available
     
     
     
206. QIN S, Jiang Y, Ou Y, Zhan Y, et al
     Mendelian randomization of circulating proteome identifies IFN-gamma as a druggable target in aplastic anemia.
     Ann Hematol. 2024 Apr 22. doi: 10.1007/s00277-024-05746.
     PubMed     Abstract available
     
     
     
207. LOMMERSE IN, Hinnen C, van Vliet LM, Schubert B, et al
     Quality of life after immune suppressive therapy in aplastic anemia.
     Ann Hematol. 2024 Apr 5. doi: 10.1007/s00277-024-05731.
     PubMed     Abstract available
     
     
     
208. DE CASTRO JNP, da Silva Costa SM, Camargo ACL, Ito MT, et al
     Comparative transcriptomic analysis of circulating endothelial cells in sickle cell stroke.
     Ann Hematol. 2024;103:1167-1179.
     PubMed     Abstract available
     
     
     
209. SHARMA A, Kumar A, Saha PK, Saha L, et al
     The role of TMPRSS6 gene polymorphism in iron resistance iron deficiency anaemia (IRIDA): a systematic review.
     Ann Hematol. 2024;103:1085-1102.
     PubMed     Abstract available
     
     
     
210. WANG J, Zhu H, Miao K
     Gilteritinib combined with venetoclax and azacitidine for relapsed acute myeloid leukemia cocurrent with pure red cell aplasia after allogeneic hematopoietic stem cell transplantation: a case report.
     Ann Hematol. 2024 Apr 1. doi: 10.1007/s00277-024-05714.
     PubMed     Abstract available
     
     
     March 2024
211. VALLEJO C, Rosell A, Xicoy B, Garcia C, et al
     A multicentre ambispective observational study into the incidence and clinical management of aplastic anaemia in Spain (IMAS study).
     Ann Hematol. 2024;103:705-713.
     PubMed     Abstract available
     
     
     
212. LEONI S, Bou-Fakhredin R, Granata F, Cassinerio E, et al
     Acute liver injury after SARS-CoV-2 vaccination and luspatercept administration in a patient with beta-thalassemia.
     Ann Hematol. 2024;103:1025-1026.
     PubMed    
     
     
     February 2024
213. SECK M, Manal B, Toure SA, Keita M, et al
     Challenges in the management of iron-deficiency anemia in Senegal, West Africa.
     Ann Hematol. 2024 Feb 3. doi: 10.1007/s00277-024-05626.
     PubMed    
     
     
     
214. ZHA Q, Shi Y, Shi Z, Huang F, et al
     Loeys-Dietz syndrome with concomitant aplastic anemia.
     Ann Hematol. 2024 Feb 2. doi: 10.1007/s00277-024-05637.
     PubMed    
     
     
     
215. SONGDEJ D, Surapolchai P, Komwilaisak P, Sripornsawan P, et al
     Molecular characteristics of hereditary red blood cell membrane disorders in Thailand: a multi-center registry.
     Ann Hematol. 2024;103:385-393.
     PubMed     Abstract available
     
     
     
216. GARCIA-MORIN M, Bardon-Cancho EJ, Belendez C, Dulin E, et al
     Madrid Newborn Sickle Cell Disease Cohort: clinical outcomes, stroke prevention and survival.
     Ann Hematol. 2024;103:373-383.
     PubMed     Abstract available
     
     
     
217. MURAKHOVSKAYA I, Crivera C, Leon A, Alemao E, et al
     Healthcare resource utilization of patients with warm autoimmune hemolytic anemia initiating first line therapy of oral corticosteroids with or without rituximab.
     Ann Hematol. 2024 Feb 1. doi: 10.1007/s00277-023-05613.
     PubMed     Abstract available
     
     
     January 2024
218. CHATTOPADHYAY S, Lionel S, Selvarajan S, Devasia AJ, et al
     Relapse and transformation to myelodysplastic syndrome and acute myeloid leukemia following immunosuppressive therapy for aplastic anemia is more common as compared to allogeneic stem cell transplantation with a negative impact on survival.
     Ann Hematol. 2024 Jan 20. doi: 10.1007/s00277-024-05621.
     PubMed     Abstract available
     
     
     
219. ZHANG Z, Wang X, Jiang J
     Screening results and mutation frequency analysis of G6PD deficiency in 1,291,274 newborns in Huizhou, China: a twenty-year experience.
     Ann Hematol. 2024;103:29-36.
     PubMed     Abstract available
     
     
     
220. ZULLO A, De Francesco V, Gatta L, Scaccianoce G, et al
     Small bowel lesions in patients with iron deficiency anaemia without overt bleeding: a multicentre study.
     Ann Hematol. 2024;103:1-4.
     PubMed     Abstract available
     
     
     
221. SCHREZENMEIER H, Kulasekararaj A, Mitchell L, de Latour RP, et al
     Predictors for improvement in patient-reported outcomes: post hoc analysis of a phase 3 randomized, open-label study of eculizumab and ravulizumab in complement inhibitor-naive patients with paroxysmal nocturnal hemoglobinuria.
     Ann Hematol. 2024;103:5-15.
     PubMed     Abstract available
     
     
     December 2023
222. DELGADINHO M, Veiga L, Ginete C, Santos B, et al
     Differential expression of adhesion molecules in sickle cell anemia and gut microbiome effect.
     Ann Hematol. 2023 Dec 28. doi: 10.1007/s00277-023-05589.
     PubMed     Abstract available
     
     
     
223. FU L, Zhang J, Wang R, Yang B, et al
     Clinical characteristics of hepatitis-associated aplastic anemia in children.
     Ann Hematol. 2023 Dec 12. doi: 10.1007/s00277-023-05566.
     PubMed     Abstract available
     
     
     
224. MCBRIDE HJ, Frazer-Abel A, Thiemann S, Lehto SG, et al
     Functional similarity of ABP 959 and eculizumab in simulated serum models of aHUS and NMOSD.
     Ann Hematol. 2023;102:3299-3309.
     PubMed     Abstract available
     
     
     November 2023
225. GONG Y, Zhang X, Chen X, Yang H, et al
     Warm autoimmune hemolytic anemia associated with SARS-CoV-2 infection responsive to eculizumab.
     Ann Hematol. 2023 Nov 27. doi: 10.1007/s00277-023-05549.
     PubMed    
     
     
     
226. STRASSER B, Heibl S, Hormann G, Haushofer A, et al
     Diamond-Blackfan anemia with very late and fatal onset aplasia in a 55-year-old patient with RPL11 mutation.
     Ann Hematol. 2023 Nov 23. doi: 10.1007/s00277-023-05553.
     PubMed    
     
     
     
227. KITAMURA W, Kobayashi H, Iseki A, Wada H, et al
     Cold agglutinin-induced acrocyanosis without hemolytic anemia.
     Ann Hematol. 2023 Nov 9. doi: 10.1007/s00277-023-05538.
     PubMed    
     
     
     
228. POPE V, Hsia CC
     Safe utilization of ruxolitinib in simultaneous primary myelofibrosis and warm autoimmune hemolytic anemia.
     Ann Hematol. 2023 Nov 6. doi: 10.1007/s00277-023-05535.
     PubMed    
     
     
     
229. LOUZAO M, Vargas MT, Meseguer E, Pedrote Amador B, et al
     Successful use of thrombopoietin analogs in thrombocytopenia associated with MYH-9 mutation.
     Ann Hematol. 2023;102:3283-3284.
     PubMed    
     
     
     
230. SUN XH, Liu Q, Wu SN, Xu WH, et al
     Cytopenia: a report of haplo-cord transplantation in twin brothers caused by a novel germline GATA1 mutation and family survey.
     Ann Hematol. 2023;102:3177-3184.
     PubMed     Abstract available
     
     
     
231. VALLEE T, Schmid I, Gloning L, Bacova M, et al
     Excellent outcome of stem cell transplantation for sickle cell disease.
     Ann Hematol. 2023;102:3217-3227.
     PubMed     Abstract available
     
     
     
232. HOCHSMANN B, Peffault de Latour R, Hill A, Roth A, et al
     Risk factors for thromboembolic events in patients with paroxysmal nocturnal hemoglobinuria (PNH): a nested case-control study in the International PNH Registry.
     Ann Hematol. 2023;102:2979-2988.
     PubMed     Abstract available
     
     
     October 2023
233. SI T, Ma X, Zhu W, Zhou Y, et al
     Comment on: Association between anemia and depression: results from NHANES 2005-2018 and Mendelian randomization analyses.
     Ann Hematol. 2023 Oct 21. doi: 10.1007/s00277-023-05496.
     PubMed    
     
     
     
234. KURITA N, Nishikii H, Maruyama Y, Suehara Y, et al
     Safety of romiplostim administered immediately after cord-blood transplantation: a phase 1 trial.
     Ann Hematol. 2023;102:2895-2902.
     PubMed     Abstract available
     
     
     
235. DEENADAYALAN V, Litvin R, Vakil J, Kanemo P, et al
     Recent national trends in outcomes and economic disparities among adult sickle cell disease-related admissions.
     Ann Hematol. 2023;102:2659-2669.
     PubMed     Abstract available
     
     
     
236. ROCCOTELLI D, Grande D, Cicco G, Palma A, et al
     Real-life experience with luspatercept in transfusion-dependent beta-thalassemia.
     Ann Hematol. 2023;102:2965-2967.
     PubMed    
     
     
     
237. CAN F, Yilmaz KN, Kosemehmetoglu OS, Akinci S, et al
     Comparison of different intravenous iron preparations in terms of total oxidant and total antioxidant status, single center data.
     Ann Hematol. 2023;102:2645-2650.
     PubMed     Abstract available
     
     
     September 2023
238. YOUSSEF MAM, Ghazaly MH, Abdelfattah MA
     Alternative treatment modality for severe aplastic anemia in a resource-limited setting: a single-institution prospective cohort study from Upper Egypt.
     Ann Hematol. 2023 Sep 13. doi: 10.1007/s00277-023-05440.
     PubMed     Abstract available
     
     
     
239. CHEN M, Ataga KI, Hankins JS, Zhang M, et al
     Age-related differences in risks and outcomes of 30-day readmission in adults with sickle cell disease.
     Ann Hematol. 2023;102:2329-2342.
     PubMed     Abstract available
     
     
     
240. SHOME DK, Das P, Akbar GA, Taha S, et al
     Molecular insights into hereditary elliptocytosis and pyropoikilocytosis: NGS uncovers multiple potential candidate genes.
     Ann Hematol. 2023;102:2343-2351.
     PubMed     Abstract available
     
     
     
241. GREWAL US, Thotamgari SR, Gaddam SJ, Lakra R, et al
     Characteristics and outcomes associated with venous thrombotic complications among patients with paroxysmal nocturnal hemoglobinuria.
     Ann Hematol. 2023;102:2631-2632.
     PubMed    
     
     
     
242. HAYASHINO K, Fujiwara Y, Isokane Y, Tobita H, et al
     Paroxysmal nocturnal hemoglobinuria with ulcerative colitis.
     Ann Hematol. 2023;102:2625-2626.
     PubMed    
     
     
     August 2023
243. SORIN B, Fadlallah J, Garzaro M, Vigneron J, et al
     Real-life use of mTOR inhibitor-based therapy in adults with autoimmune cytopenia highlights strong efficacy in relapsing/refractory multi-lineage autoimmune cytopenia.
     Ann Hematol. 2023;102:2059-2068.
     PubMed     Abstract available
     
     
     
244. VIPRAKASIT V, Hamdy MM, Hassab HMA, Sherief LM, et al
     Patient preference for deferasirox film-coated versus dispersible tablet formulation: a sequential-design phase 2 study in patients with thalassemia.
     Ann Hematol. 2023;102:2039-2049.
     PubMed     Abstract available
     
     
     
245. MUSALLAM KM, Ahmed W, Almarshoodi MO, Trad O, et al
     Establishment of the Abu Dhabi Emirate Thalassemia Longitudinal Cohort (AD-TLC): leveraging the power of observation.
     Ann Hematol. 2023;102:2277-2278.
     PubMed    
     
     
     
246. SHIMAZU Y, Mizumoto C, Chonabayashi K, Hanyu Y, et al
     Successful treatment with cyclosporine of pure red cell aplasia induced by obinutuzumab bendamustine therapy.
     Ann Hematol. 2023;102:2291-2292.
     PubMed    
     
     
     July 2023
247. WANG Y, Guo D, Sui C, Qu Z, et al
     Association between anemia and depression: results from NHANES 2005-2018 and mendelian randomization analyses.
     Ann Hematol. 2023 Jul 22. doi: 10.1007/s00277-023-05374.
     PubMed     Abstract available
     
     
     
248. HAMMAMI MB, Qasim A, Thakur R, Vegivinti CTR, et al
     Rasburicase-induced hemolytic anemia and methemoglobinemia: a systematic review of current reports.
     Ann Hematol. 2023 Jul 19. doi: 10.1007/s00277-023-05364.
     PubMed     Abstract available
     
     
     
249. LIN F, Dong X, Zhang Y, Cheng Y, et al
     Time-dependent analysis of the impact on early cytomegalovirus reactivation of HLA mismatch and acute graft-versus-host disease after allogeneic hematopoietic cell transplantation from related donors in acquired aplastic anemia.
     Ann Hematol. 2023 Jul 13. doi: 10.1007/s00277-023-05332.
     PubMed     Abstract available
     
     
     
250. ZHAO J, Ma L, Zheng M, Su L, et al
     Meta-analysis of the results of haploidentical transplantation in the treatment of aplastic anemia.
     Ann Hematol. 2023 Jul 13. doi: 10.1007/s00277-023-05339.
     PubMed     Abstract available
     
     
     
251. BODLA ZH, Hashmi M, Niaz F, Farooq U, et al
     Timing matters: An analysis of the relationship between red cell transfusion timing and hospitalization outcomes in sickle cell crisis patients using the National Inpatient Sample database.
     Ann Hematol. 2023;102:1669-1676.
     PubMed     Abstract available
     
     
     
252. DINGLI D, Maciejewski JP, Larratt L, Go RS, et al
     Relationship of paroxysmal nocturnal hemoglobinuria (PNH) granulocyte clone size to disease burden and risk of major vascular events in untreated patients: results from the International PNH Registry.
     Ann Hematol. 2023;102:1637-1644.
     PubMed     Abstract available
     
     
     
253. AU TY, Wisniewski OW, Benjamin S, Kubicki T, et al
     G6PD deficiency-does it alter the course of COVID-19 infections?
     Ann Hematol. 2023;102:1629-1636.
     PubMed     Abstract available
     
     
     June 2023
254. CANNAS G, Poutrel S, Heiblig M, Labussiere H, et al
     Sickle cell disease and acute leukemia: one case report and an extensive review.
     Ann Hematol. 2023 Jun 3:1-11. doi: 10.1007/s00277-023-05294.
     PubMed     Abstract available
     
     
     May 2023
255. ARAUJO COSTA E, de Paula Ayres-Silva J
     Global profile of anemia during pregnancy versus country income overview: 19 years estimative (2000-2019).
     Ann Hematol. 2023 May 26. doi: 10.1007/s00277-023-05279.
     PubMed     Abstract available
     
     
     
256. WU LQ, Huang LF, Yang H, Ye BD, et al
     Comparison of haploidentical-allogeneic hematopoietic stem cell transplantation and intensive immunosuppressive therapy for patients with severe aplastic anemia with an absolute neutrophil count of zero: a retrospective study.
     Ann Hematol. 2023 May 17. doi: 10.1007/s00277-023-05256.
     PubMed     Abstract available
     
     
     
257. NIU H, Yan L, Yang L, Zhang M, et al
     High TOX expression on CD8(+) T cells in pure red cell aplasia.
     Ann Hematol. 2023;102:1247-1255.
     PubMed     Abstract available
     
     
     
258. DONGERDIYE R, Bokde M, More TA, Saptarshi A, et al
     Targeted next-generation sequencing identifies eighteen novel mutations expanding the molecular and clinical spectrum of PKLR gene disorders in the Indian population.
     Ann Hematol. 2023;102:1029-1036.
     PubMed     Abstract available
     
     
     
259. BELISARIO AR, Simoes E Silva AC, Moura ICG, Carneiro-Proietti AB, et al
     Estimated glomerular filtration rate in Brazilian adults with sickle cell disease: results from the REDS-III multicenter cohort study.
     Ann Hematol. 2023;102:1019-1027.
     PubMed     Abstract available
     
     
     April 2023
260. ABDEL-SALAM A, Bassiouni ST, Goher AM, Shafie ES, et al
     Autoimmune Hemolytic Anemia in the Pediatric Age Group: The Egyptian Experience.
     Ann Hematol. 2023 Apr 24. doi: 10.1007/s00277-023-05230.
     PubMed     Abstract available
     
     
     
261. TSILIKA M, Mitrou J, Antonakos N, Tseti IK, et al
     An active new formulation of iron carried by aspartyl casein for iron-deficiency anemia: results of the ACCESS trial.
     Ann Hematol. 2023 Apr 6. doi: 10.1007/s00277-023-05197.
     PubMed     Abstract available
     
     
     
262. JONGKRAIJAKRA S, Doungngern T, Sripakdee W, Lekhakula A, et al
     A randomized controlled trial of thrice-weekly versus thrice-daily oral ferrous fumarate treatment in adult patients with iron-deficiency anemia.
     Ann Hematol. 2023 Apr 3:1-8. doi: 10.1007/s00277-023-05198.
     PubMed     Abstract available
     
     
     
263. IGLESIAS-VAZQUEZ L, Gimeno M, Coronel P, Caspersen IH, et al
     Maternal factors associated with iron deficiency without anaemia in early pregnancy: ECLIPSES study.
     Ann Hematol. 2023;102:741-748.
     PubMed     Abstract available
     
     
     
264. ZHANG Y, Pan J, Kang H, Peng S, et al
     Characteristics of inpatients with newly diagnosed multiple myeloma in hematology, nephrology, and orthopedic departments.
     Ann Hematol. 2023;102:801-809.
     PubMed     Abstract available
     
     
     March 2023
265. YANG K, Nie W, Huang Q, Liao G, et al
     Hematopoietic cell transplantation for congenital dyserythropoietic anemia IV caused by compound heterozygous KLF1 mutations.
     Ann Hematol. 2023 Mar 31. doi: 10.1007/s00277-023-05175.
     PubMed    
     
     
     
266. DING K, Liu Z, Ren Y, Liu H, et al
     Use of roxadustat (FG-4592) in ruxolitinib-treatment-related anemia of two myelofibrosis patients.
     Ann Hematol. 2023 Mar 13. doi: 10.1007/s00277-022-04997.
     PubMed    
     
     
     
267. AHMADI M, Beiranvand S, Poormansouri S, Matbouei M, et al
     Sense of coherence or self-efficacy as predictors of health-related quality of life in sickle cell disease patients.
     Ann Hematol. 2023;102:519-528.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Anemia is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum